SCHEMBL3600173

SCHEMBL3600173

CC(C)NC(=O)N1CCC[C@H]1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 6/20 0.57
REN P00797 4/20 0.57
LMNA P02545 2/20 0.57
HSD17B10 Q99714 2/20 0.57
KDM4E B2RXH2 1/20 0.57
F2 P00734 1/20 0.57
LTA4H P09960 1/20 0.57
MAPT P10636 1/20 0.57
PEPD P12955 1/20 0.57
ALOX15 P16050 1/20 0.57
PTGS1 P23219 1/20 0.57
HTR2A P28223 1/20 0.57
PTGS2 P35354 1/20 0.57
HRH1 P35367 1/20 0.57
THPO P40225 1/20 0.57
PMP22 Q01453 1/20 0.57
ACE2 Q9BYF1 1/20 0.57
RAB9A P51151 1/20 0.55
ITGB3 P05106 1/20 0.52
ITGB1 P05556 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134719 1.00 ACE (0.57) ACERENLMNAHSD17B10KDM4E
SCHEMBL18676315 0.83 ITGB3 (0.54) ACERENLMNAHSD17B10KDM4E
SCHEMBL3966373 0.83 ITGB3 (0.54) ACERENLMNAHSD17B10KDM4E
SCHEMBL25194678 0.82 FKBP1A (0.59) ACELMNAITGB3ITGB1ITGAV
SCHEMBL25266163 0.82 FKBP1A (0.59) ACELMNAITGB3ITGB1ITGAV
SCHEMBL25206506 0.82 FKBP1A (0.59) ACELMNAITGB3ITGB1ITGAV
SCHEMBL25202155 0.82 FKBP1A (0.59) ACELMNAITGB3ITGB1ITGAV
SCHEMBL25197324 0.82 FKBP1A (0.59) ACELMNAITGB3ITGB1ITGAV
SCHEMBL25265364 0.82 FKBP1A (0.59) ACELMNAITGB3ITGB1ITGAV
SCHEMBL25206507 0.82 FKBP1A (0.59) ACELMNAITGB3ITGB1ITGAV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183280-B2 FAP inhibitors VANTIA LIMITED (GB) 2012-05-22 US disclosed
US-20100081701-A1 FAP inhibitors VANTIA LIMITED (GB) 2010-04-01 US disclosed
EP-1919864-A2 FAP INHIBITORS Ferring B.V. (NL) 2008-05-14 EP disclosed
WO-2007085895-A2 FAP INHIBITORS FERRING B.V. (US) 2007-08-02 WO disclosed
EP-1760076-A1 FAP Inhibitors FERRING B.V. (NL) 2007-03-07 EP disclosed
US-4217130-A DECREASING ACID CONTENT WITH PHENYL- OR BENZYLCARBAMOYLPROLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 1980-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081701-A1 FAP inhibitors FAP, APC, SERPINB1 ACE 127/4885REN 1830/4885LMNA 2975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.